Phase 1Active, not recruiting
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes
- Sponsor
- Alveus Therapeutics, Inc. (Industry)
- Enrolment
- 180 planned
- Conditions
- Overweight or Obese Adults; Overweight or Obese, Type 2 Diabetes
- Interventions
- ALV-100; Placebo
- Ages
- adults, older adults
- Registry
- NCT07399678
Full record on ClinicalTrials.gov
From the registry
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Primary outcomes
- Safety and tolerability
History
Primary completion expected
Last registry update
Registered
Started